TGR5 in the cholangiociliopathies

Tatyana V. Masyuk, Anatoliy I. Masyuk, Nicholas F La Russo

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

A plasma membrane-bound G protein-coupled receptor, TGR5, that transmits bile acid signaling into a cellular response primarily via the cAMP pathway is expressed in human and rodent cholangiocytes and is localized to multiple, diverse subcellular compartments, including primary cilia. Ciliary-associated TGR5 plays an important role in cholangiocyte physiology and may contribute to a group of liver diseases referred to as the 'cholangiociliopathies', which include polycystic liver disease (PLD) and, possibly, cholangiocarcinoma and primary sclerosing cholangitis. Based on our observations that (1) ciliated and nonciliated cholangiocytes respond to TGR5 activation differently (i.e. the level of cAMP increases in nonciliated cholangiocytes but decreases in ciliated cells) and (2) hepatic cysts are derived from cholangiocytes that are characterized by both malformed cilia and increased cAMP levels, we hypothesized that TGR5-mediated cAMP signaling in cystic cholangiocytes contributes to hepatic cystogenesis. Indeed, our studies show that TGR5 is overexpressed and mislocalized in cystic cholangiocytes, and when activated by ligands, results in increased intracellular cAMP levels, cholangiocyte hyperproliferation and cyst growth. Our studies also show that genetic elimination of TGR5 in an animal model of PLD inhibits hepatic cystogenesis. Collectively, these data suggest the involvement of TGR5 in PLD and that TGR5 targeting in cystic cholangiocytes may have therapeutic potential.

Original languageEnglish (US)
Pages (from-to)420-425
Number of pages6
JournalDigestive Diseases
Volume33
Issue number3
DOIs
StatePublished - Jun 9 2015

Fingerprint

Cilia
Cysts
Sclerosing Cholangitis
Cholangiocarcinoma
Liver
G-Protein-Coupled Receptors
Bile Acids and Salts
Liver Diseases
Hepatocytes
Rodentia
Animal Models
Cell Membrane
Ligands
Growth
Polycystic liver disease
Therapeutics

Keywords

  • Cholangiociliopathies
  • Cholangiocytes
  • Cilia
  • Hepatic cysts
  • Polycystic liver disease

ASJC Scopus subject areas

  • Gastroenterology

Cite this

TGR5 in the cholangiociliopathies. / Masyuk, Tatyana V.; Masyuk, Anatoliy I.; La Russo, Nicholas F.

In: Digestive Diseases, Vol. 33, No. 3, 09.06.2015, p. 420-425.

Research output: Contribution to journalArticle

Masyuk, Tatyana V. ; Masyuk, Anatoliy I. ; La Russo, Nicholas F. / TGR5 in the cholangiociliopathies. In: Digestive Diseases. 2015 ; Vol. 33, No. 3. pp. 420-425.
@article{206ae3c509e74a76b182d901346c6ff8,
title = "TGR5 in the cholangiociliopathies",
abstract = "A plasma membrane-bound G protein-coupled receptor, TGR5, that transmits bile acid signaling into a cellular response primarily via the cAMP pathway is expressed in human and rodent cholangiocytes and is localized to multiple, diverse subcellular compartments, including primary cilia. Ciliary-associated TGR5 plays an important role in cholangiocyte physiology and may contribute to a group of liver diseases referred to as the 'cholangiociliopathies', which include polycystic liver disease (PLD) and, possibly, cholangiocarcinoma and primary sclerosing cholangitis. Based on our observations that (1) ciliated and nonciliated cholangiocytes respond to TGR5 activation differently (i.e. the level of cAMP increases in nonciliated cholangiocytes but decreases in ciliated cells) and (2) hepatic cysts are derived from cholangiocytes that are characterized by both malformed cilia and increased cAMP levels, we hypothesized that TGR5-mediated cAMP signaling in cystic cholangiocytes contributes to hepatic cystogenesis. Indeed, our studies show that TGR5 is overexpressed and mislocalized in cystic cholangiocytes, and when activated by ligands, results in increased intracellular cAMP levels, cholangiocyte hyperproliferation and cyst growth. Our studies also show that genetic elimination of TGR5 in an animal model of PLD inhibits hepatic cystogenesis. Collectively, these data suggest the involvement of TGR5 in PLD and that TGR5 targeting in cystic cholangiocytes may have therapeutic potential.",
keywords = "Cholangiociliopathies, Cholangiocytes, Cilia, Hepatic cysts, Polycystic liver disease",
author = "Masyuk, {Tatyana V.} and Masyuk, {Anatoliy I.} and {La Russo}, {Nicholas F}",
year = "2015",
month = "6",
day = "9",
doi = "10.1159/000371696",
language = "English (US)",
volume = "33",
pages = "420--425",
journal = "Digestive Diseases",
issn = "0257-2753",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - TGR5 in the cholangiociliopathies

AU - Masyuk, Tatyana V.

AU - Masyuk, Anatoliy I.

AU - La Russo, Nicholas F

PY - 2015/6/9

Y1 - 2015/6/9

N2 - A plasma membrane-bound G protein-coupled receptor, TGR5, that transmits bile acid signaling into a cellular response primarily via the cAMP pathway is expressed in human and rodent cholangiocytes and is localized to multiple, diverse subcellular compartments, including primary cilia. Ciliary-associated TGR5 plays an important role in cholangiocyte physiology and may contribute to a group of liver diseases referred to as the 'cholangiociliopathies', which include polycystic liver disease (PLD) and, possibly, cholangiocarcinoma and primary sclerosing cholangitis. Based on our observations that (1) ciliated and nonciliated cholangiocytes respond to TGR5 activation differently (i.e. the level of cAMP increases in nonciliated cholangiocytes but decreases in ciliated cells) and (2) hepatic cysts are derived from cholangiocytes that are characterized by both malformed cilia and increased cAMP levels, we hypothesized that TGR5-mediated cAMP signaling in cystic cholangiocytes contributes to hepatic cystogenesis. Indeed, our studies show that TGR5 is overexpressed and mislocalized in cystic cholangiocytes, and when activated by ligands, results in increased intracellular cAMP levels, cholangiocyte hyperproliferation and cyst growth. Our studies also show that genetic elimination of TGR5 in an animal model of PLD inhibits hepatic cystogenesis. Collectively, these data suggest the involvement of TGR5 in PLD and that TGR5 targeting in cystic cholangiocytes may have therapeutic potential.

AB - A plasma membrane-bound G protein-coupled receptor, TGR5, that transmits bile acid signaling into a cellular response primarily via the cAMP pathway is expressed in human and rodent cholangiocytes and is localized to multiple, diverse subcellular compartments, including primary cilia. Ciliary-associated TGR5 plays an important role in cholangiocyte physiology and may contribute to a group of liver diseases referred to as the 'cholangiociliopathies', which include polycystic liver disease (PLD) and, possibly, cholangiocarcinoma and primary sclerosing cholangitis. Based on our observations that (1) ciliated and nonciliated cholangiocytes respond to TGR5 activation differently (i.e. the level of cAMP increases in nonciliated cholangiocytes but decreases in ciliated cells) and (2) hepatic cysts are derived from cholangiocytes that are characterized by both malformed cilia and increased cAMP levels, we hypothesized that TGR5-mediated cAMP signaling in cystic cholangiocytes contributes to hepatic cystogenesis. Indeed, our studies show that TGR5 is overexpressed and mislocalized in cystic cholangiocytes, and when activated by ligands, results in increased intracellular cAMP levels, cholangiocyte hyperproliferation and cyst growth. Our studies also show that genetic elimination of TGR5 in an animal model of PLD inhibits hepatic cystogenesis. Collectively, these data suggest the involvement of TGR5 in PLD and that TGR5 targeting in cystic cholangiocytes may have therapeutic potential.

KW - Cholangiociliopathies

KW - Cholangiocytes

KW - Cilia

KW - Hepatic cysts

KW - Polycystic liver disease

UR - http://www.scopus.com/inward/record.url?scp=84930579735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930579735&partnerID=8YFLogxK

U2 - 10.1159/000371696

DO - 10.1159/000371696

M3 - Article

C2 - 26045278

AN - SCOPUS:84930579735

VL - 33

SP - 420

EP - 425

JO - Digestive Diseases

JF - Digestive Diseases

SN - 0257-2753

IS - 3

ER -